다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

홈
인베스팅
주식
미국
NASDAQ
Silexion Therapeutics Corporation (SLXNW)
Silexion Therapeutics Corporation (SLXNW) 뉴스

SLXNW

Silexion Therapeutics (SLXNW)

Silexion Therapeutics Corporation

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:SLXNW

일자	시간	출처	헤드라인	심볼	기업
2025/02/13	06:33	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2025/01/30	23:26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2025/01/28	22:56	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2025/01/17	20:56	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2025/01/17	20:44	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2025/01/16	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2025/01/16	06:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2025/01/15	20:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2025/01/15	07:02	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2025/01/14	20:19	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2025/01/14	20:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/12/18	20:00	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/12/17	21:08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/12/10	23:42	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/12/10	23:41	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/12/10	22:48	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/29	20:06	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/29	20:05	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/29	20:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/27	20:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/23	06:34	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/23	06:32	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/23	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/20	20:15	Edgar (US Regulatory)	Form SC 13D - General Statement of Acquisition of Beneficial Ownership	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/20	06:10	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/20	06:08	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/20	06:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/14	23:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/14	22:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SLXNW	Silexion Therapeutics Corporation
2024/11/14	06:05	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:SLXNW	Silexion Therapeutics Corporation

검색 관련기사 보기:NASDAQ:SLXNW

BNP Paribas (QX)

Verizon Communications

American Express

JP Morgan Chase

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관